Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DU26QH
|
|||
| Drug Name |
IONIS-GHR-LRx
|
|||
| Synonyms |
Cimdelirsen
Click to Show/Hide
|
|||
| Indication | Acromegaly [ICD-11: 5A60.0; ICD-10: E22.0; ICD-9: 253] | Phase 2 | [1] | |
| Company |
Ionis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth hormone receptor (GHR) | Target Info | . | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Pathway Interaction Database | Notch-mediated HES/HEY network | |||
| Reactome | Prolactin receptor signaling | |||
| Growth hormone receptor signaling | ||||
| WikiPathways | Endochondral Ossification | |||
| Prolactin receptor signaling | ||||
| Growth hormone receptor signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04522180) An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.